Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has earned a consensus rating of “Hold” from the ten ratings firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $5.35.

A number of analysts have issued reports on ACHN shares. Ladenburg Thalmann Financial Services reduced their price target on shares of Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating on the stock in a report on Tuesday, September 12th. Leerink Swann reiterated a “buy” rating and issued a $5.00 price target on shares of Achillion Pharmaceuticals in a report on Monday, December 11th. Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, September 14th. Robert W. Baird reiterated a “neutral” rating and issued a $4.00 price target (down from $5.00) on shares of Achillion Pharmaceuticals in a report on Tuesday, September 12th. Finally, Chardan Capital reiterated a “neutral” rating on shares of Achillion Pharmaceuticals in a report on Sunday, September 17th.

In other Achillion Pharmaceuticals news, major shareholder & Johnson Johnson sold 18,367,346 shares of Achillion Pharmaceuticals stock in a transaction on Monday, November 20th. The shares were sold at an average price of $2.75, for a total value of $50,510,201.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 7.24% of the company’s stock.

Large investors have recently modified their holdings of the business. Dimensional Fund Advisors LP grew its stake in shares of Achillion Pharmaceuticals by 51.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 613,006 shares of the biopharmaceutical company’s stock worth $2,581,000 after buying an additional 207,204 shares in the last quarter. Deschutes Portfolio Strategy LLC grew its stake in shares of Achillion Pharmaceuticals by 358.6% in the 2nd quarter. Deschutes Portfolio Strategy LLC now owns 116,630 shares of the biopharmaceutical company’s stock worth $535,000 after buying an additional 91,200 shares in the last quarter. Senzar Asset Management LLC purchased a new position in shares of Achillion Pharmaceuticals in the 2nd quarter worth $4,966,000. Candriam Luxembourg S.C.A. purchased a new position in shares of Achillion Pharmaceuticals in the 3rd quarter worth $1,976,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Achillion Pharmaceuticals by 11.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 611,634 shares of the biopharmaceutical company’s stock worth $2,808,000 after buying an additional 62,515 shares in the last quarter. 76.93% of the stock is owned by institutional investors and hedge funds.

Achillion Pharmaceuticals (NASDAQ ACHN) traded down $0.13 on Thursday, reaching $2.76. 9,657,138 shares of the company’s stock traded hands, compared to its average volume of 2,870,000. Achillion Pharmaceuticals has a fifty-two week low of $2.69 and a fifty-two week high of $5.66.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.04. During the same quarter in the prior year, the company earned ($0.15) earnings per share. sell-side analysts predict that Achillion Pharmaceuticals will post -0.63 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was first posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.dailypolitical.com/2017/12/17/brokerages-set-achillion-pharmaceuticals-inc-achn-target-price-at-5-35.html.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.